He didn’t say which actual manufacturing steps could be carried out nor if Sanofi was already holding talks with opponents. Vaccine manufacturing requires a number of phases, from analysis to filling and packing.
Last month, Sanofi and Britain’s GlaxoSmithKline mentioned a COVID-19 vaccine they’re collectively creating had confirmed an inadequate immune response in older individuals, delaying its launch to late subsequent yr, in a setback for each corporations.
“Given the current adjustments… we now have some momentary flexibility with our manufacturing capacities,” the spokesman mentioned.
“We are exploring all choices and at present assessing the technical feasibility of performing some manufacturing steps to assist different COVID-19 vaccines producers,” he mentioned.
The spokesman mentioned because of laws and particular manufacturing processes, Sanofi could circuitously produce the drug element of one other vaccine.
Sanofi can also be engaged on one other COVID-19 vaccine candidate with the United States’ Translate Bio which makes use of mRNA expertise. Phase I trials are anticipated to start out this quarter.